Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study

DUBLIN & CAMBRIDGE, United Kingdom & BRISBANE, Australia--(BUSINESS WIRE)--Inflazome (, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces the successful completion of a Phase I study of its investigational drug, Somalix. Somalix is a small molecule, peripherally-restricted inhibitor of the NLRP3 inflammasome. The Phase I data showed excellent safety and tolerability, while pharmacokinetics showed linear increase w

Full Story →